Symbols / JAGX $0.42 +4.07% Jaguar Health, Inc.

Healthcare • Biotechnology • United States • NCM
JAGX Chart
About

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 5.17M
Enterprise Value 31.08M Income -40.29M Sales 11.79M
Book/sh 0.85 Cash/sh 0.94 Dividend Yield —
Payout 0.00% Employees 49 IPO —
P/E — Forward P/E -0.07 PEG —
P/S 0.44 P/B 0.49 P/C —
EV/EBITDA -1.01 EV/Sales 2.64 Quick Ratio 0.14
Current Ratio 0.81 Debt/Eq 731.82 LT Debt/Eq —
EPS (ttm) -2.58 EPS next Y -5.68 EPS Growth —
Revenue Growth -0.80% Earnings 2026-04-15 ROA -38.01%
ROE -4.12% ROIC — Gross Margin 81.92%
Oper. Margin -234.77% Profit Margin 0.00% Shs Outstand 12.42M
Shs Float 2.61M Short Float 3.50% Short Ratio 0.80
Short Interest — 52W High 15.48 52W Low 0.31
Beta 0.29 Avg Volume 3.91M Volume 112.69K
Target Price $7.50 Recom None Prev Close $0.40
Price $0.42 Change 4.07%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.50
Mean price target
2. Current target
$0.41
Latest analyst target
3. DCF / Fair value
$-22.00
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.41
Low
$7.50
High
$7.50
Mean
$7.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-05-19 init First Berlin — → Buy $60
News
RSS: Latest JAGX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-11 BOCHNOWSKI JAMES J. Director — 6,363 $0.00 $0
2025-12-11 MICEK JOHN J III Director — 7,377 $0.00 $0
2025-12-11 KING STEVEN R. PH.D. Officer — 11,740 $0.00 $0
2025-12-11 CONTE LISA A. Chief Executive Officer — 28,592 $0.00 $0
2025-12-11 SIEGEL JONATHAN B Director — 7,377 $0.00 $0
2025-12-11 LIZAK CAROL R. Chief Financial Officer — 11,740 $0.00 $0
2025-12-11 WOLIN JONATHAN S General Counsel — 11,740 $0.00 $0
2025-12-11 JAYASURIYA ANULA Director — 5,870 $0.00 $0
2025-12-11 CHATURVEDI PRAVIN R Officer — 11,740 $0.00 $0
2025-05-16 KING STEVEN R. PH.D. Officer — 1 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
11.69
+19.75%
9.76
-18.36%
11.96
+175.80%
4.33
Operating Revenue
15.58
+14.53%
13.61
-9.40%
15.02
-4.45%
15.72
Cost Of Revenue
1.96
-4.03%
2.04
+0.89%
2.02
-13.46%
2.33
Reconciled Cost Of Revenue
1.96
-4.03%
2.04
+0.89%
2.02
-13.46%
2.33
Gross Profit
9.73
+26.02%
7.72
-22.27%
9.94
+396.35%
2.00
Operating Expense
40.56
-2.59%
41.64
-6.11%
44.35
+7.98%
41.08
Research And Development
16.54
-11.05%
18.60
+5.38%
17.65
+17.03%
15.08
Selling General And Administration
24.02
+4.23%
23.05
-13.69%
26.70
+2.72%
26.00
Selling And Marketing Expense
4.09
+24.70%
3.28
-36.31%
5.16
-42.04%
8.89
General And Administrative Expense
19.93
+0.83%
19.77
-8.28%
21.55
+26.00%
17.10
Salaries And Wages
9.10
-1.35%
9.23
-16.50%
11.05
+93.01%
5.73
Other Gand A
10.01
+3.61%
9.66
-2.12%
9.87
-11.05%
11.10
Total Expenses
42.52
-2.66%
43.68
-5.80%
46.37
+6.82%
43.41
Operating Income
-30.83
+9.11%
-33.92
+1.44%
-34.41
+11.92%
-39.07
Total Operating Income As Reported
-30.83
+10.09%
-34.29
+0.36%
-34.41
+15.46%
-40.71
EBITDA
-36.66
-10.66%
-33.13
+0.75%
-33.38
+21.21%
-42.37
Normalized EBITDA
-28.42
+9.29%
-31.33
-0.51%
-31.17
+21.40%
-39.66
Reconciled Depreciation
2.36
-1.26%
2.39
+4.19%
2.29
+26.42%
1.81
EBIT
-39.02
-9.86%
-35.52
+0.43%
-35.67
+19.26%
-44.18
Total Unusual Items
-8.24
-358.03%
-1.80
+18.49%
-2.21
+18.44%
-2.71
Total Unusual Items Excluding Goodwill
-8.24
-358.03%
-1.80
+18.49%
-2.21
+18.44%
-2.71
Special Income Charges
1.25
-62.57%
3.33
+252.08%
-2.19
-190.44%
-0.75
Other Special Charges
-1.25
+66.32%
-3.70
-269.04%
2.19
+190.44%
0.75
Impairment Of Capital Assets
0.00
-100.00%
0.37
0.00
—
Net Income
-38.49
+6.80%
-41.30
+12.97%
-47.45
+9.77%
-52.59
Pretax Income
-39.25
+6.32%
-41.90
+13.42%
-48.40
+7.99%
-52.60
Net Non Operating Interest Income Expense
-0.23
+96.38%
-6.38
+49.84%
-12.72
-26.53%
-10.05
Interest Expense Non Operating
0.23
-96.38%
6.38
-49.84%
12.72
+51.09%
8.42
Net Interest Income
-0.23
+96.38%
-6.38
+49.84%
-12.72
-26.53%
-10.05
Interest Expense
0.23
-96.38%
6.38
-49.84%
12.72
+51.09%
8.42
Other Income Expense
-8.19
-412.13%
-1.60
-27.21%
-1.26
+63.79%
-3.47
Other Non Operating Income Expenses
0.05
-74.50%
0.20
-78.95%
0.95
+224.18%
-0.77
Gain On Sale Of Security
-9.48
-85.07%
-5.12
-25525.00%
-0.02
+98.98%
-1.95
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-39.25
+6.32%
-41.90
+13.42%
-48.40
+7.99%
-52.60
Net Income From Continuing Operation Net Minority Interest
-38.49
+6.80%
-41.30
+12.97%
-47.45
+9.77%
-52.59
Net Income From Continuing And Discontinued Operation
-38.49
+6.80%
-41.30
+12.97%
-47.45
+9.77%
-52.59
Net Income Continuous Operations
-39.25
+6.32%
-41.90
+13.42%
-48.40
+7.99%
-52.60
Minority Interests
0.76
+26.29%
0.60
-36.13%
0.94
+18720.00%
0.01
Normalized Income
-30.25
+23.41%
-39.50
+12.70%
-45.25
+9.30%
-49.89
Net Income Common Stockholders
-38.49
+6.80%
-41.30
+12.97%
-47.45
+9.77%
-52.59
Otherunder Preferred Stock Dividend
—
—
—
0.00
Diluted EPS
-130.69
+95.12%
-2,678.17
+91.79%
-32,614.43
+73.34%
-122,313.95
Basic EPS
-130.69
+95.12%
-2,678.17
+91.79%
-32,614.43
+73.34%
-122,313.95
Basic Average Shares
0.29
+1809.95%
0.02
+959.86%
0.00
+238.37%
0.00
Diluted Average Shares
0.29
+1809.95%
0.02
+959.86%
0.00
+238.37%
0.00
Diluted NI Availto Com Stockholders
-38.49
+6.80%
-41.30
+12.97%
-47.45
+9.77%
-52.59
Rent And Landing Fees
0.82
-6.84%
0.88
+39.43%
0.63
+123.05%
0.28
Rent Expense Supplemental
0.82
-6.84%
0.88
+39.43%
0.63
+123.05%
0.28
Total Other Finance Cost
—
—
—
1.63
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
53.42
+5.24%
50.76
+6.98%
47.45
-10.91%
53.27
Current Assets
32.20
+15.15%
27.96
+25.28%
22.32
-21.50%
28.43
Cash Cash Equivalents And Short Term Investments
8.00
+23.70%
6.47
+18.28%
5.47
-67.93%
17.05
Cash And Cash Equivalents
8.00
+23.70%
6.47
+18.28%
5.47
-67.93%
17.05
Cash Financial
8.00
+23.70%
6.47
+18.28%
5.47
-67.93%
17.05
Receivables
1.65
-24.59%
2.18
-11.47%
2.47
+15.07%
2.14
Accounts Receivable
1.53
-22.37%
1.97
+4.68%
1.88
+9.95%
1.71
Other Receivables
0.12
-44.70%
0.22
-63.10%
0.59
+35.17%
0.43
Inventory
10.35
+12.58%
9.19
+30.82%
7.02
+43.35%
4.90
Raw Materials
1.85
-10.06%
2.06
-2.09%
2.10
+68.35%
1.25
Work In Process
7.41
+13.66%
6.52
+81.08%
3.60
+30.40%
2.76
Finished Goods
1.09
+76.91%
0.61
-53.55%
1.32
+48.43%
0.89
Prepaid Assets
—
—
—
4.34
Other Current Assets
12.20
+20.58%
10.12
+37.49%
7.36
+69.65%
4.34
Total Non Current Assets
21.23
-6.90%
22.80
-9.28%
25.13
+1.21%
24.83
Net PPE
1.40
-16.27%
1.67
-1.47%
1.70
-2.13%
1.73
Gross PPE
1.91
-10.48%
2.14
+1.71%
2.10
+3.40%
2.03
Accumulated Depreciation
-0.51
-10.32%
-0.47
-15.10%
-0.40
-35.57%
-0.30
Properties
0.00
0.00
0.00
0.00
Land And Improvements
0.40
+0.00%
0.40
+0.00%
0.40
+0.00%
0.40
Buildings And Improvements
0.82
-16.60%
0.98
—
—
Machinery Furniture Equipment
0.22
-21.63%
0.28
+220.45%
0.09
+39.68%
0.06
Other Properties
0.48
+0.00%
0.48
-70.50%
1.62
+2.80%
1.57
Goodwill And Other Intangible Assets
18.48
-8.14%
20.12
-10.35%
22.44
-0.94%
22.65
Other Intangible Assets
18.48
-8.14%
20.12
-10.35%
22.44
-0.94%
22.65
Other Non Current Assets
1.35
+33.20%
1.01
+1.71%
0.99
+123.09%
0.45
Total Liabilities Net Minority Interest
46.93
+2.32%
45.87
-6.03%
48.81
+17.86%
41.41
Current Liabilities
19.70
+40.87%
13.99
-53.90%
30.34
+96.10%
15.47
Payables And Accrued Expenses
7.20
-17.95%
8.77
-37.22%
13.97
+16.00%
12.05
Payables
5.40
+2.54%
5.27
-17.63%
6.39
+17.54%
5.44
Accounts Payable
5.29
+6.27%
4.97
-14.36%
5.81
+17.83%
4.93
Current Accrued Expenses
1.80
-48.75%
3.51
-53.75%
7.58
+14.73%
6.61
Total Tax Payable
0.11
-60.96%
0.29
-50.09%
0.58
+14.71%
0.51
Current Debt And Capital Lease Obligation
12.34
+136.57%
5.21
-68.14%
16.37
+377.98%
3.42
Current Debt
12.04
+147.34%
4.87
-69.36%
15.88
+398.84%
3.18
Other Current Borrowings
12.04
+147.34%
4.87
-69.36%
15.88
+398.84%
3.18
Current Capital Lease Obligation
0.30
-14.08%
0.35
-27.95%
0.48
+101.25%
0.24
Current Deferred Liabilities
0.17
0.00
—
—
Current Deferred Revenue
0.17
0.00
—
—
Other Current Liabilities
—
—
—
0.00
Total Non Current Liabilities Net Minority Interest
27.23
-14.59%
31.88
+72.61%
18.47
-28.80%
25.94
Long Term Debt And Capital Lease Obligation
24.19
-24.12%
31.88
+72.61%
18.47
-28.80%
25.94
Long Term Debt
23.50
-24.17%
30.99
+74.67%
17.74
-29.09%
25.02
Long Term Capital Lease Obligation
0.69
-22.57%
0.89
+22.21%
0.72
-21.11%
0.92
Non Current Deferred Liabilities
0.55
0.00
—
—
Non Current Deferred Revenue
0.55
0.00
—
—
Preferred Securities Outside Stock Equity
2.48
0.00
—
—
Stockholders Equity
7.29
+46.85%
4.96
+855.10%
-0.66
-105.66%
11.61
Common Stock Equity
7.29
+46.85%
4.96
+855.10%
-0.66
-105.66%
11.61
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
0.53
+979.73%
0.05
+3263.71%
0.00
+238.37%
0.00
Ordinary Shares Number
0.53
+979.73%
0.05
+3263.71%
0.00
+238.37%
0.00
Additional Paid In Capital
354.23
+12.86%
313.86
+17.56%
266.97
+15.52%
231.10
Retained Earnings
-346.48
-12.40%
-308.25
-15.47%
-266.95
-21.62%
-219.49
Gains Losses Not Affecting Retained Earnings
-0.47
+28.37%
-0.65
+4.12%
-0.68
0.00
Minority Interest
-0.79
-1135.94%
-0.06
+90.84%
-0.70
-388.84%
0.24
Other Equity Adjustments
-0.47
+28.37%
-0.65
+4.12%
-0.68
—
Total Equity Gross Minority Interest
6.49
+32.61%
4.90
+461.14%
-1.36
-111.44%
11.85
Total Capitalization
30.79
-14.37%
35.95
+110.42%
17.09
-53.36%
36.63
Working Capital
12.49
-10.60%
13.98
+274.31%
-8.02
-161.85%
12.96
Invested Capital
42.83
+4.91%
40.82
+23.81%
32.97
-17.20%
39.82
Total Debt
36.53
-1.53%
37.09
+6.48%
34.84
+18.63%
29.36
Net Debt
27.54
-6.30%
29.39
+4.38%
28.16
+152.42%
11.15
Capital Lease Obligations
0.98
-20.18%
1.23
+2.15%
1.21
+4.23%
1.16
Net Tangible Assets
-11.19
+26.14%
-15.15
+34.38%
-23.10
-109.20%
-11.04
Tangible Book Value
-11.19
+26.14%
-15.15
+34.38%
-23.10
-109.20%
-11.04
Interest Payable
0.00
-99.44%
0.72
-86.90%
5.49
+58.83%
3.46
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-29.38
+11.61%
-33.24
-0.42%
-33.10
+5.34%
-34.97
Cash Flow From Continuing Operating Activities
-29.38
+11.61%
-33.24
-0.42%
-33.10
+5.34%
-34.97
Net Income From Continuing Operations
-39.03
+6.77%
-41.87
+14.68%
-49.08
+6.70%
-52.60
Depreciation Amortization Depletion
2.36
-1.26%
2.39
+4.19%
2.29
+26.42%
1.81
Depreciation
2.36
-1.26%
2.39
+4.19%
2.29
+26.42%
1.81
Depreciation And Amortization
2.36
-1.26%
2.39
+4.19%
2.29
+26.42%
1.81
Other Non Cash Items
0.28
-97.88%
13.38
+6.33%
12.58
+142.55%
5.19
Stock Based Compensation
1.64
-22.30%
2.11
-36.35%
3.32
-16.51%
3.97
Asset Impairment Charge
0.00
-100.00%
0.37
0.00
—
Operating Gains Losses
-1.11
+69.64%
-3.65
-266.71%
2.19
-10.22%
2.44
Gain Loss On Investment Securities
—
—
—
1.63
Unrealized Gain Loss On Investment Securities
9.48
+85.07%
5.12
+24304.76%
0.02
-98.92%
1.95
Change In Working Capital
-3.01
+72.88%
-11.10
-150.65%
-4.43
-295.32%
2.27
Change In Receivables
0.53
+76.51%
0.30
+170.78%
-0.42
-117.43%
2.42
Changes In Account Receivables
0.44
+600.00%
-0.09
+48.24%
-0.17
-106.02%
2.82
Change In Inventory
-1.16
+46.61%
-2.17
-1.93%
-2.12
-0.28%
-2.12
Change In Prepaid Assets
-1.51
+69.81%
-5.01
-221.22%
-1.56
-95.98%
-0.80
Change In Payables And Accrued Expense
-0.80
+78.92%
-3.81
-802.95%
0.54
-83.02%
3.19
Change In Accrued Expense
-1.13
+61.73%
-2.96
-720.83%
-0.36
-111.87%
3.03
Change In Payable
0.33
+138.36%
-0.85
-194.79%
0.90
+470.89%
0.16
Change In Account Payable
0.33
+138.36%
-0.85
-194.79%
0.90
+470.89%
0.16
Change In Other Working Capital
0.72
—
—
—
Change In Other Current Assets
-0.34
-1876.47%
-0.02
+96.91%
-0.55
-34.80%
-0.41
Change In Other Current Liabilities
-0.45
-14.47%
-0.39
-25.08%
-0.32
-1557.89%
-0.02
Investing Cash Flow
-0.23
0.00
+100.00%
-1.68
-27816.67%
-0.01
Cash Flow From Continuing Investing Activities
-0.23
0.00
+100.00%
-1.68
-27816.67%
-0.01
Net PPE Purchase And Sale
-0.02
0.00
+100.00%
-0.08
-1183.33%
-0.01
Purchase Of PPE
-0.02
0.00
+100.00%
-0.08
-1183.33%
-0.01
Capital Expenditure
-0.23
—
-1.68
-27816.67%
-0.01
Net Intangibles Purchase And Sale
-0.21
0.00
+100.00%
-1.60
0.00
Purchase Of Intangibles
-0.21
0.00
+100.00%
-1.60
0.00
Financing Cash Flow
31.20
-8.84%
34.23
+47.65%
23.18
-47.24%
43.94
Cash Flow From Continuing Financing Activities
31.20
-8.84%
34.23
+47.65%
23.18
-47.24%
43.94
Net Issuance Payments Of Debt
-0.10
+0.00%
-0.10
-102.58%
3.88
-57.20%
9.05
Issuance Of Debt
—
0.00
-100.00%
3.98
-63.78%
10.97
Repayment Of Debt
-0.10
+0.00%
-0.10
+0.00%
-0.10
+94.80%
-1.92
Long Term Debt Issuance
—
0.00
-100.00%
3.98
-63.78%
10.97
Long Term Debt Payments
-0.10
+0.00%
-0.10
+0.00%
-0.10
+94.80%
-1.92
Net Long Term Debt Issuance
-0.10
+0.00%
-0.10
-102.58%
3.88
-57.20%
9.05
Net Common Stock Issuance
31.91
-0.59%
32.10
+56.88%
20.46
-39.06%
33.58
Proceeds From Stock Option Exercised
0.00
-100.00%
1.24
0.00
-100.00%
2.04
Net Other Financing Charges
-0.61
-260.00%
0.38
+132.87%
-1.16
-58.14%
-0.73
Changes In Cash
1.59
+61.12%
0.98
+108.49%
-11.60
-229.43%
8.96
Effect Of Exchange Rate Changes
-0.05
-460.00%
0.01
-6.25%
0.02
0.00
Beginning Cash Position
6.47
+18.28%
5.47
-67.93%
17.05
+110.77%
8.09
End Cash Position
8.00
+23.70%
6.47
+18.28%
5.47
-67.93%
17.05
Free Cash Flow
-29.61
+10.91%
-33.24
+4.42%
-34.78
+0.56%
-34.98
Interest Paid Supplemental Data
0.01
-60.00%
0.04
+52.17%
0.02
-17.86%
0.03
Common Stock Issuance
31.91
-0.59%
32.10
+56.88%
20.46
-39.06%
33.58
Earnings Losses From Equity Investments
0.14
+170.59%
0.05
0.00
—
Issuance Of Capital Stock
31.91
-2.45%
32.71
+59.86%
20.46
-39.06%
33.58
Net Preferred Stock Issuance
0.00
-100.00%
0.61
0.00
—
Preferred Stock Issuance
0.00
-100.00%
0.61
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category